Prostate Cancer - Results from #940

Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer. May 1, 2024

Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence. May 1, 2024

Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [68Ga]Ga-PSMA-11-PET Examinations. May 1, 2024

Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer. April 30, 2024

Real-world treatment patterns and medical costs of prostate cancer patients in Switzerland - A claims data analysis. April 30, 2024

Comparative Effectiveness of Partial Gland Cryoablation Versus Robotic Radical Prostatectomy for Cancer Control. April 30, 2024

A systematic review of cytoreductive prostatectomy outcomes and complications in oligometastatic disease. April 30, 2024

Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project. April 30, 2024

Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. April 30, 2024

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. April 30, 2024

Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey-Holden Prostate Cancer Academy Meeting. April 30, 2024

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study. April 29, 2024

Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer. April 29, 2024

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. April 29, 2024

The State of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Prostate Cancer in 2024. April 29, 2024

Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial). April 29, 2024

Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter. April 27, 2024

Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis. April 26, 2024

Zeb1-controlled metabolic plasticity enables remodeling of chromatin accessibility in the development of neuroendocrine prostate cancer. April 26, 2024

Prostate-specific Membrane Antigen: Alpha-labeled Radiopharmaceuticals. April 26, 2024

Page 48 of 1435